The document provides an overview and market forecast for atopic dermatitis (AD) from 2017 to 2027 in 7 major markets. It finds that in 2016, 40 million people had AD globally, with uncontrolled AD affecting approximately 7 million in the US. The market size for AD was $2.2 billion in 2016, and is expected to grow due to new drug approvals and launches until 2027. Upcoming new drugs from 2022 to 2021 may further impact the market size for pruritus associated with AD. Key market drivers include increasing disease prevalence and new treatment options, while lack of awareness and low efficacy existing drugs pose barriers.

1. Market Insights, Epidemiology and
Market Forecast - 2027

2. Atopic Dermatitis
2
0201Atopic dermatitis (AD) is a
chronic inflammatory skin
disease and is characterized
by widespread skin lesions,
which manifest as red, itchy,
swollen, cracked, weeping
lesions with crusting/scaling,
intractable pruritus (most
common and persistent
disease that is prevalent) and
enhanced susceptibility to
bacterial and viral skin
infections.
Atopic Dermatitis is also
classified as
Controlled Atopic
Dermatitis and
Uncontrolled Atopic
Dermatitis on the basis of
the disease controlled by
using therapies.

3. In 2016 the total number of prevalent population of AD
was estimated to be around 40 million and that of
Pruritus in AD was estimated as 20.5 million in 7MM.
The prevalent population of Uncontrolled
AD in the U.S. was found to be
approximately 7 million in 2016.
United States accounts for the maximum
number of AD cases followed by Europe and
Japan.
DelveInsight estimates that the prevalent population
of AD will significantly increase during the forecasted
period in 7 MM’s.
The prevalence of uncontrolled Atopic Dermatitis is higher in adults as compared to children.
Prevalence
3

4. According to the latest report of DelveInsight,
“Atopic Dermatitis – Market Insight, Epidemiology & Market Forecast, 2027”
following can be inferred:
Market Scenario
4
1
2
3
4
In 2016 the market size of AD was estimated to be
around USD 2.2 billion in 7MM.
Market size of Pruritus in Atopic Dermatitis was estimated
to be USD 1.8 billion in 2016 in 7MM.
As per the estimates, a higher growth has been seen in
the AD market during the period of 2015-2027 due to the
expected launch of new therapies.

5. Treatment Options
5
Corticosteroids
Immunosuppressants
Calcineurin inhibitors
Elidel
Protopic
Desonate
Pimecrolimus
Eucrisa (Pfizer)
Dupilumab (Regeneron
Pharmaceuticals
/Sanofi)
The market is dominated
by the use of these for the
treatment of Atopic
Dermatitis.
Following are the various
approved drugs which are
also available
Market has seen a positive growth after
the approval of the following drugs in
2016 and 2017 respectively due to their
novel mechanism of action.

6. Upcoming therapies
6
2022
2022 Nemolizumab
(Galderma Pharma)
Tralokinumab
(LEO Pharma)
2021 RVT-501
(Roivant Sciences)
2021 OPA-15406
(Otsuka Pharmaceutical)
The launch of these upcoming
therapies are expected to create
a positive impact on the market
size of Pruritus in Atopic
Dermatitis.
Launch Year

7. 7
DRIVERS BARRIERS
Increasing prevalence, emerging drugs,
growing government and pharmaceutical
company’s initiatives, and advancement in
treatment are the market drivers for Atopic
Dermatitis.
On the other hand, lack of awareness, no
approved drug, challenges in performing
clinical trials, and use of low efficacy drugs are
some of the market barriers.
Market Drivers and Market Barriers
DRUG
LAUNCH

8. Complete Information
For complete information please click below
Or
Write to us at
info@delveinsight.com
CLICK HERE
DelveInsight © 2017 | All rights reserved

9. About DelveInsight
DelveInsight, market research and consulting firm, provides end to
end comprehensive solutions to the Life Science Industry.
We help our customers in best decision making through our
expertise in research & analysis and comes out with unmatched data
& forecasts
Vision
“Insight across the value chain”
to help organizations make
important business decisions
through the use and analysis of actionable
market intelligence
Mission
• To be the most trusted marketing
research firm & business consulting
firm worldwide.
• To be a renowned and premier data
driven solution providers among
Pharma & Biotech companies.
DelveInsight © 2017 | All rights reserved

10. • Trends Analysis
• Physicians & Patients Perception
• KOLs
• Market Size
• Market Dynamics
• Market Assessment
Service Offerings at DelveInsight
Comprehensive solution for strategic business decisions
Access over 3000+ Reports
• API
• Market & Pipeline
• Indication & Epidemiology
• Drug Sales Forecast
• Indication Forecast
• Late Stage Pipeline Analysis
• Asset Prioritization
• Brand Optimization
• Portfolio Expansion
Opportunity Assessment for
• Licensing
• Market Access
• Partnership
• Competitive landscape
• Clinical Trials
• Therapeutic Assessment
• Primary Analytics
• News-Letters
• Conference Tracking
• Clinical Trials Tracking
Market
Intelligence
Consulting
SociAlytics
Pipeline
Forecasting
DelveInsight © 2017 | All rights reserved

11. Add a Slide Title - 5
Contact Us:
info@delveinsight.com
+91-11-4568 9769
www.delveinsight.com
blog/delveInsight/
twitter/delveInsight
LinkedIn/delveInsight